Tenofovir Disoproxil Fumarate + Buprenorphine = Unknown or no reaction

Effect on Concentration

Tenofovir Disoproxil Fumarate
No change
Applies within class?
No
Buprenorphine
No change
Applies within class?
No

Pharmacologic Effects

Tenofovir Disoproxil Fumarate
Effect
N/A
Applies within class?
No
Buprenorphine
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 24-Jul-2018

Summary

Sources

Tenofovir Disoproxil Fumarate vs Buprenorphine ^

Study Design

Authors report the results of a study designed to examine the interaction between buprenorphine and the nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine (ddI), lamivudine (3TC), and tenofovir (TDF). Opioid-dependent, buprenorphine/naloxone-maintained, HIV-negative volunteers (n = 27) participated in two 24-hour sessions to determine (1) pharmacokinetics of buprenorphine alone and (2) pharmacokinetics of both buprenorphine and either ddI, 3TC, or TDF.

Study Results

Among buprenorphine/naloxone-maintained study participants, no significant changes in buprenorphine pharmacokinetics were observed following ddI, 3TC, or TDF administration. Buprenorphine had no significant effect on NRTI concentrations. Tenofovir’s effects on Buprenorphine and its metabolites are described below: Pharmacokinetic Parameter Pre-tenofovir Post- tenofovir P value Buprenorphine AUC 36.8 (5.4) 40.07 (6.2) 0.42 Cmax 4.72 (1.03) 5.64 (1.18) 0.21 Cmin 0.94 (0.17) 0.94 (0.17) 0.99 Norbuprenorphine AUC 47.9 (8.4) 55.3 (9.4) 0.29 Cmax 3.54 (0.7) 3.95 (0.68) 0.41 Cmin 1.65 (0.32) 1.7 (0.28) 0.85 Buprenorphine 3-glucuronide AUC 35.7 (14) 26.7 (5.6) 0.49 Cmax 7.32 (1.93) 8.82 (1.74) 0.29 Cmin 0.6 (0.23) 0.5 (0.12) 0.54 Norbuprenorphine 3-glucuronide AUC 198 (26) 204 (37) 0.83 Cmax 17 (2.6) 16 (3.2) 0.68 Cmin 6.04 (0.92) 5.99 (1.14) 0.97

Study Conclusions

Concomitant use of buprenorphine with TDF results in neither a significant pharmacokinetic nor pharmacodynamic interaction. As such these drugs can be coadministered without dose adjustment for opioid addicted patients using tenofovir.

References

Baker J, Rainev PM, Moody DE, Morse GD, Ma Q, McCance-Catz EE. Interactions between buprenorphine and antivirals: nucleos(t)ide reverse transcriptase inhibitors (nrti) didanosine, lamivudine, and tenofovir. American Journal On Addictions. 2010; 1: 17-29.